Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Muraglitazar (BMS-298585) is a PPAR α/γ dual agonist for the treatment of type 2 diabetes and associated dyslipidemia. Muraglitazar shows potent activity in vitro at human PPARα and PPARγ with EC50 of 320 nM and 110 nM respectively.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 293.00 | |
5 mg | In stock | $ 719.00 | |
10 mg | In stock | $ 987.00 | |
25 mg | In stock | $ 1,490.00 | |
50 mg | In stock | $ 1,980.00 | |
100 mg | In stock | $ 2,750.00 |
Description | Muraglitazar (BMS-298585) is a PPAR α/γ dual agonist for the treatment of type 2 diabetes and associated dyslipidemia. Muraglitazar shows potent activity in vitro at human PPARα and PPARγ with EC50 of 320 nM and 110 nM respectively. |
Synonyms | Pargluva, BMS-298585 |
Molecular Weight | 516.54 |
Formula | C29H28N2O7 |
CAS No. | 331741-94-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: Soluble
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Muraglitazar 331741-94-7 DNA Damage/DNA Repair Metabolism PPAR BMS298585 Pargluva BMS 298585 BMS-298585 inhibitor inhibit